Acute-phase reactant proteins and complement components and inhibitors in patients with ovarian cancer.
D000328:Adult; D000368:Aged; D003174:Complement C1 Inactivator Proteins / Q000032:analysis; D003180:Complement C3b Inactivator Proteins / Q000032:analysis; D011415:Complement Factor B / Q000032:analysis; D003169:Complement Inactivator Proteins / Q000032:analysis*; D003165:Complement System Proteins / Q000032:analysis*; D003536:Cystadenocarcinoma / Q000097:blood; D005260:Female; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008875:Middle Aged; D009961:Orosomucoid / Q000032:analysis; D010051:Ovarian Neoplasms / Q000097:blood*; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000511:alpha-Macroglobulins / Q000032:analysis*
D003174:Complement C1 Inactivator Proteins; D003180:Complement C3b Inactivator Proteins; D003169:Complement Inactivator Proteins; D006242:Haptoglobins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009961:Orosomucoid; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D003165:Complement System Proteins; D011415:Complement Factor B